FINPROVE - targeted anticancer therapy study
The Finprove study investigating the potential for targeted drug therapy in patients with advanced cancer who no longer have other treatment options. Our Comprehensive Cancer Center coordinates the study which is open at all university hospitals in Finland.
Targeted anticancer therapy
Based on changes in the cancer genome, the number of targeted anticancer drugs has increased significantly. There are many anticancer drugs in clinical use that are based on the characteristics of the cancer genome. However, the approved indications for use of these drugs restrict their use in every type of cancer. This study provides the opportunity to use approved medications outside of current indications.
European collaboration
The study is part of European EU projects that leverage the results and expertise of similar studies in order to achieve results faster.
The EU collaboration provides a lot of new training and increased awareness of personalized cancer treatment for officials and patients.
Other FINPROVE centers
- Tampere University Hospital (opens in new window, links to another website)
- Wellbeing services county of North Savo (opens in new window, links to another website)
- Turku University Hospital (opens in new window, links to another website)
- Oulu University Hospital (opens in new window, links to another website)